Foundation for Prader-Willi Blog (39)

Saniona reports positive Tesomet Phase 2a clinical results in adolescent patients with Prader-Willi syndrome

In a phase 2a study involving 18 patients with PWS (9 adults, and 9 adolescents) Tesomet reduced body weight and improved BMI and reduced hyperphagia to very low levels. Tesomet appears to be highly efficacious in adult and adolescent patients and wa...

September 23, 2019 Read More

Topics: News

Evaluating Exercise Programs for People with PWS: New Study

The Foundation for Prader-Willi Research and the Prader-Willi Research Foundation Australia are jointly supporting a new research project, led by Dr. Nora Shields of La Trobe University, evaluating the effects of exercise training in individuals with...

September 18, 2019 Read More

Topics: News, Research

A Call To Action: Why PWS Clinical Trials Need to Be Full

Treatments for Prader-Willi syndrome are urgently needed. Today, we are closer than ever to the treatments for which we have been waiting, but we need all hands on deck to ensure our efforts can take us to the finish line. Here's why.

September 10, 2019 Read More

Topics: News

PWS Receives Specific Disease Code to Track Medical Care and Outcomes

The National Center for Health Statistics has designated a specific ICD-10 code for Prader-Willi syndrome (PWS). Previously PWS was included as one of number of genetic disorders ICD-10-CM code Q87.1, which contains a large group of genetic disorders...

September 9, 2019 Read More

Debunking the Myths of Clinical Trials

Nearly 500 people with PWS are needed this year to fill PWS specific clinical trials. These trials are incredibly important to the PWS community and are necessary in order to bring treatments for some of the most challenging aspects of PWS. Here, we ...

September 3, 2019 Read More

Pitolisant approved for treatment of excessive daytime sleepiness in adult patients with narcolepsy

Harmony Biosciences has announced that the U.S. Food and Drug Administration has approved WAKIX® (pitolisant) for the treatment of excessive daytime sleepiness (EDS) in adult patients with narcolepsy.

August 15, 2019 Read More

Topics: News